Extracellular vesicles (EVs) are the common designation for ectosomes, microparticles and microvesicles serving dominant roles in intercellular communication . Both viable and dying cells release EVs to the extracellular environment for transfer of cell, immune and infectious materials . Defined morphologically as lipid bi-layered structures EVs show molecular, biochemical, distribution, and entry mechanisms similar to viruses within cells and tissues . In recent years their functional capacities have been harnessed to deliver biomolecules and drugs and immunological agents to specific cells and organs of interest or disease . Interest in EVs as putative vaccines or drug delivery vehicles are substantial . The vesicles have properties of receptors nanoassembly on their surface . EVs can interact with specific immunocytes that include antigen presenting cells (dendritic cells and other mononuclear phagocytes) to elicit immune responses or affect tissue and cellular homeostasis or disease . Due to potential advantages like biocompatibility, biodegradation and efficient immune activation, EVs have gained attraction for the development of treatment or a vaccine system against the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection . In this review efforts to use EVs to contain SARS CoV-2 and affect the current viral pandemic are discussed . An emphasis is made on mesenchymal stem cell derived EVs' as a vaccine candidate delivery system.